The heartbreaking story of a Coventry bride's untimely death just weeks after her wedding underscores the urgent need for better access to clinical trials for brain tumours. But here's where it gets controversial: despite concerted efforts, very few patients with brain tumours are currently participating in research, which is slowing down vital medical progress. Let's delve deeper into this critical issue.
In January 2026, a deeply emotional story emerged about Natalie, a 31-year-old woman from Coventry who was diagnosed with an aggressive brain tumour back in 2017. Throughout her battle, Natalie remained resilient, sharing her experiences through a blog to raise awareness about brain tumours, refusing to let her illness overshadow her identity. Her journey involved multiple surgeries, intensive radiotherapy, chemotherapy sessions, and even fundraising efforts to afford immunotherapy treatments across Germany—costing around £56,000 per round, excluding travel expenses.
Unfortunately, Natalie passed away in November 2021, just seven weeks after her wedding. Her mother, Liz Paul, who works as an Involvement Champion for The Brain Tumour Charity, has expressed strong support for a new initiative aimed at transforming how patients access clinical trials: the Access to Clinical Trials for Brain Tumours (ACT-BT).
But why is this initiative so vital? Currently, brain tumour clinical trials lag behind other cancers in participation rates, with only about 12% of patients taking part—an alarmingly low figure. A recent report by The Brain Tumour Charity highlighted key barriers such as lack of awareness—less than half of surveyed patients knew about existing research opportunities—and geographical hurdles, with many living far from specialized centres where trials take place. Additionally, there’s often insufficient support to help patients manage cognitive and physical side effects that could hinder trial participation.
The ACT-BT project is a collaborative effort between The Brain Tumour Charity and the University of Leeds, designed to expand access to these crucial trials. It will enable doctors across the UK to refer adult patients with primary brain tumours to a panel of experienced clinical trial experts via an easy online form. A dedicated multidisciplinary team of ten specialists from across the UK will meet weekly to review cases and match patients with suitable trials, providing personalized guidance.
Professor Susan Short, a leading researcher from the University of Leeds, emphasizes that the goal is to eliminate barriers that prevent patients from engaging in research. "By improving accessibility, we can speed up the discovery of new treatments and ensure they reach patients sooner," she explains.
The project is set to be fully operational by late spring, supported by funding from The Brain Tumour Charity, covering setup costs and staff time. This initiative aims to provide a more equitable pathway for patients and their families to participate, making clinical trials less daunting and more accessible.
And this is the part most people miss: involving patients and their caregivers at every step is crucial for creating a system that truly meets their needs. To this end, the charity is collaborating with Brainstrust, inviting up to ten patients and loved ones to share their insights, ensuring their voices shape the development of the panel and its processes.
Dr. Helen Bulbeck, co-founder of Brainstrust, highlights this point: "Patient involvement is key. When those affected by brain tumours help design and guide these processes, participation becomes not just possible but meaningful and supportive."
In essence, the launch of ACT-BT promises to become a pivotal step toward closing the gap between need and opportunity—giving more brain tumour patients a chance to benefit from innovative treatments. While it’s still in its early stages, with plans to expand, the question remains: will this initiative truly change the landscape of brain tumour research, or will systemic barriers continue to hinder progress? Are we doing enough to ensure that every patient, regardless of location or circumstance, can access potentially life-saving trials? Share your thoughts below—this is a conversation that needs to happen.
